DNA quantification as a prognostic factor in prostatic adenocarcinoma

Analytical and Quantitative Cytology and Histology

Volumn 18, Issue 4, 1996, Pages 330-336

  Azúa, Javier ^a   Romeo, Peña ^a   Valle, Jörge ^b   Azúa Jr , Javier ^c  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^c Facultad de Medicina ^*

Author keywords

adenocarcinoma; DNA; image cytometry; prognosis; prostatic neoplasms

Indexed keywords

DNA;

ARTICLE; ASPIRATION BIOPSY; CANCER SURVIVAL; CONTROLLED STUDY; DNA DETERMINATION; ENTROPY; HISTOGRAM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA;

ADENOCARCINOMA; DNA, NEOPLASM; HUMANS; IMAGE CYTOMETRY; MALE; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 0029836863     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Adolfsson J, Ronstrom L, Hedlund PO, Löwhagen T, Cristensen J, Tribukait B: The prognostic value of modal desoxiribonucleic acid in low grade, low stage untreated prostate cancer. J Urol 1990;144:1404-1407
2. Adolfsson J, Tribukait B: Evaluation of tumor progression by repeated fine needle biopsies in prostate adenocarcinoma: Modal DNA value and cytological differentiation. J Urol 1990;144:1408-1410
3. Al-Abadi H, Nager R: Nuclear DNA analysis: DNA heterogeneity in the monitoring of patients with locally advanced prostatic carcinoma. Eur Urol 1992;22:303-310
4. Alfthan O, Klintrup HE, Koivunmiemi A, et al Cytological aspiration biopsy and Vim Silverman biopsy in the diagnosis of the prostatic carcinoma. Ann Chir Gynaecol 1970; 59:226-230
5. Auer G, Caspersson T, Wallgren A: DNA content and survival in mammary carcinoma. Analyt Quant Cytol Histol 1980;2:161-165
6. Azúa J: Citología por punción aspiración con aguja fina. Barcelona, Salvat Editores, 1987
7. Babiarz J, Peters JM, Miles B, Crissman JD: Comparison of DNA content in primary and lymph node metastases in prostate adenocarcinoma Analyt Quant Cytol Histol 1993;15:158-164
8. Badalament RA, O'Toole RV,Young DC, Drago JR: DNA ploidy and prostatic specific antigen as prognostic factors in clinically resectable prostate cancer. Cancer 1991;67:3014-3023
9. Ballentina Carter H, Riehle RA, Koizune JH, Amberson J,Vaughan ED: Fine needle aspiration of the abnormal prostate: A cytohistological correlation. J.Urol 1986;135:294
10. Bichel P, Frediksen P, Kjaer T, et al: Flow microfluorometry and transrectal fine needle biopsy in the classification of human prostatic carcinoma. Cancer 1977;40:1206-1211
11. Bishop D,Olivier JA: A study of transrectal aspiration biopsies of the prostate, with particular regard to prognostic evaluation. J Urol 1977;117:313-316
12. Bumpus HC: Carcinoma of the prostate: A clinical study of 1000 cases. Surg Gynecol Obstet 1926;2:150-155
13. Catalona WJ, Stein AJ, Fair WR: Grading errors in prostate needle biopsies: Relation to the accuracy of tumor grade in predicting pelvic lymph node metastases. J Urol 1982;127: 919
14. Dekernion JB: Aspiration biopsy of the prostate: The urologist́s viewpoint. Semin Urol 1983;1:166-168
15. Ekman H, Hedberg P, Persson PS: Cytological versus histological examination of needle biopsy specimens in the diagnosis of prostate carcinoma. Br J Urol 1967;39:544-548
16. Epstein N: Prostatic biopsy: A morphologic correlation of aspiration cytology with needle biopsy histology. Cancer 1976; 38:2078-2084
17. Esposti PL, Franzén S: Transrectal aspiration biopsy of the prostate. Scand J Nephrol Urol 1980;55:49
18. Ferrer Roca O: Olga'Scan Software de análisis textural con aplicaciones citologicas: I. Cuantificación de DNA. Citologia 1989;121-128
19. Fleming C, Wasson JH, Albretsen PC, Barry MJ, Wennberg JE: A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 1993;269:2650-2658
20. Fordham MVP, Burdge AH, Matthews J, Williams G, Cooke T: Prostatic carcinoma cell DNA content measured by flow cytometry and its relation to clinical outcome. Br J Surg 1986;73:400-403
21. Forsslund G, Esposti PL, Nilsson B, Zetterberg A: The prognostic significance of nuclear DNA content in prostatic carcinoma. Cancer 1992;69:1432-1439
22. Forsslund G, Zetterberg A. Ploidy level determinations in high grade and low grade malignant variants of prostatic carcinoma. Cancer Res 1990;50:4281-4285
23. Frankfurt OS, Chin JL, Englander LS, et al: Relationship between DNA ploidy, glandular differentiation and tumor spread in human prostate cancer. Cancer Res 1985;45: 1418-1423
24. Gill GW, Frots JK, Miller KA: A new formula for half oxidized hematoxylin solution that neither overstains nor requires differentiation. Acta Cytol 1974;18:300-311
25. Góinez Aracil V, Peg MT, Azúa J: Utilización del análisis de imagen en el diagnóstico de las hiperplasias y carcinomas de próstata. Citologia 1985;7:71-75
26. Gómez Aracil V, Sanz Esponera J, Azua blanco J: Estudio de las hiperplasias y carcinomas de próstata mediante citodiagnóstico por punción transrectal y su correlación con la histopatología. Patología 1983;16:331-342
27. Greene D, Taylor S, Wheeler T, Scardino P: DNA ploidy by image analysis of individual foci of prostate cancer: A preliminary report. Cancer Res 1991;51:4084-4089
28. Hanash KA, Utz DC, Cook EN, Taylor WF, Titus JL. Carcinoma of the prostate: A 15 year follow-up J Urol 1972; 107:450
29. Jewett HJ: The case for radical perineal prostatectomy. J Urol 1970;103:195-203
30. Jewett HJ: The present status of radical prostatectomy for stages A and B prostatic cancer. Urol Clin North Am 1975; 2:105-124
31. Johannson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo U: High 10 year survival rate in patients with early, untreated prostatic cancer. JAMA 1992;267. 2191-2196
32. Johannson JE, Adami HO, Andersson SO, Bergstrom R, Krusemo U, Kraaz W: Natural history of localised prostatic cancer. Lancet 1989;2:799-803
33. Jones EC, McNeal J, Bruchovsky N, De Jong G: DNA content in prostatic adenocarcinoma. Cancer 1990;66:752-757
34. Kramer SA, Spahr J, Brendler CHB, Glenn JF, Paulson DF: Experience with Gleason's histopathological grading in prostatic cancer. J Urol 1980;124:223-225
35. Layfield LJ, Mukamel E, Hiborne LH, et al: Cytological grading of prostatic aspiration biopsy: A comparison with the Gleason grading system. J Urol 1987;38:798-800
36. Lieber MM: DNA content/ploidy as prognostic factors in prostate cancer. Prostate 1992;(suppl)4:119-124
37. Lundberg S, Carstersen J, Rundquist I: DNA flow cytometry and histopathological grading of paraffin-embedded prostate biopsy specimens in a survival study. Cancer Res 1987;47:1973-1977
38. Miller J, Horsfall DJ, Marshall VR, Rao DM, Leong SY: The prognostic value of desoxyribonucleic acid flow cytometric analysis in stage D2 prostatic carcinoma. J Urol 1991;145: 1192-1196
39. Mills SE, Fowler JE: Gleason histologic grading of prostatic carcinoma: Correlations between biopsy and prostatectomy specimens. Cancer 1986;57:346-350
40. Mostofi FK: Grading of prostatic carcinoma. Cancer Chemother Rep 1975,59:111-115
41. Nesbit RM, Plumb RT: Prostatic carcinoma: a followup on 795 patients treated prior to the endocrine era and a comparison of survival rates between these and patients treated by endocrine therapy. Surgery 1946;20:263-270
42. Paulson DF: Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 1982;128:502-510
43. Persons DL, Gibney DJ, Katzmann JA, Lieber MM, Farrow GM, Jenkins RB: Use of fluorescent in situ hybridization for desoxyribonucleic acid ploidy analysis of prostatic adenocarcinoma. J Urol 1992;150:120-125
44. Peters Gee J, Miles B, Cerny J, Gaba A, Jacobsen G, Crissman J: Prognostic significance of DNA quantitation in stage D1 prostate carcinoma with the use of image analysis. Cancer 1992;70:1159-1165
45. Piaton E, Mouriquand J, Berger N, et al.: Valeur du grade cytologique dans l'adenocarcinome prostatique. J Urol (Paris) 1990;96:211-216
46. Ritchie AW, Dorey F, Layfield LJ, Hannah J, Lovrekovich H, Dekernion JB: Relationship of DNA content to conventional prognostic factors in clinically localised carcinoma of the prostate. Br J Urol 1988;62:254-260
47. Ronstron L, Tribukait B, Esposti PL: DNA pattern and cytological findings in fine needle aspiration of untreated prostatic tumors: A flow cytofluorometric study. Prostate 1981;2: 79-84
48. Schemeller NT, Jocham D, Staehler G, et al: Cytologic regression grading of hormone treated prostatic cancer. Prostate 1986;9:1-17
49. Seppelt V, Sprenger E, Hedderich J: Investigation of automated DNA diagnosis and grading prostatic cancer. Analyt Quant Cytol Histol 1986;8:152-160
50. Sprenger E, Michaelis WE, Vogt-Schaden M, et al.: The significance of DNA flow through fluorescence cytometry for the diagnosis of prostate carcinoma. Beitr Pathol 1976;292: 159-165
51. Stenkvist B, Johansson-Browen I: Image analysis cytology for DNA determination in breast and prostate cancer. Acta Oncol 1991;30:911-916
52. Stenkvist B, Olding-Stenkvist E: Cytological and DNA characteristics of hyperplasia inflammation and cancer of the prostate. Eur J Cancer Clin Oncol 1990;26:261-267
53. Stenkvist B, Stande G: Entropy as an algorithm for the statistical description of DNA cytometric data obtained by image analysis microscopy. Analyt Cell Pathol 1990;2: 159-165
54. Stephenson RA, James BC, Gay H, Fair WR, Whitmore WF, Melamed MR: Flow cytometry of prostate cancer: Relationship of DNA content to survival. Cancer Res 1987;47:2504-2509
55. Tribukait B, Esposti PL, Ronstrom L: Tumor ploidy for characterization of prostatic carcinoma: Flow cytofluorometric DNA studies using aspiration biopsy material. Scand J Urol Nephrol 1980;55:59-65
56. Tribukait B, Ronstrom L, Esposti PL: Quantitative and qualitative aspects of flow DNA measurements related to the cytologic grade in prostatic carcinoma. Analyt Quant Cytol 1983;5:107-112
57. Utz DC, Farrow GM: Pathologic differentiation and prognosis of prostatic carcinoma. JAMA 1969;209:1701-1705
58. Walsh PC: Fine needle aspiration biopsy of the prostate: Why has it taken so long to accept? J Urol 1986;135:334-338
59. Wang N, Stenkvist B, Tribukait B: Morphometry of nuclei of the normal and malignant prostate in relation to DNA ploidy. Analyt Quant Cytol Histol 1992;14:210-216
60. Withmore WF: Management of clinically localized prostatic cancer: An unresolved problem. JAMA 1993;269:2676-2677
61. Withmore WF: Natural history and staging of prostate cancer. Urol Clin North Amer 1984;11:205-215
62. Zincke H, Bergstralh E, Larson-Keller JJ, et al.: Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Cancer 1992;70:311-323